Company news

Zevra Therapeutics, Inc. news in 2025

Zevra Therapeutics, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Zevra Therapeutics Executes Distribution Agreement to Broaden Access to MIPLYFFA for the Treatment of Niemann-Pick Disease Type C

December 30, 2025

Zevra Therapeutics Executes Distribution Agreement to Broaden Access to MIPLYFFA® for the Treatment of Niemann-Pick Disease Type C (NPC)

December 28, 2025

Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

December 11, 2025

Zevra Therapeutics, Inc. Appoints Alicia Secor to Board of Directors; Announces Retirement of Wendy Dixon, PhD

December 1, 2025

Zevra Therapeutics, Inc. Announces CFO Transition

November 19, 2025

Zevra Reports Third Quarter 2025 Financial Results and Corporate Update

November 4, 2025

Zevra Therapeutics to Participate in the Guggenheim Healthcare Innovation Conference

October 28, 2025

Zevra Therapeutics Announces Details for Q3 2025 Financial Results Call

October 26, 2025

Zevra Therapeutics Announces Upcoming Oral Presentation at the International Niemann-Pick Disease Alliance (INPDA) Meeting and Poster Presentations at the Child Neurology Society (CNS) Conference on MIPLYFFA® (arimoclomol) and OLPRUVA® (sodium phenylbutyrate)

September 18, 2025

Zevra Therapeutics Announces Upcoming Oral Presentation at the International Niemann-Pick Disease Alliance (INPDA) Meeting and Poster Presentations at the Child Neurology Society (CNS) Conference on MIPLYFFA® (arimoclomol) and OLPRUVA® (sodium phenylb...

September 17, 2025

Zevra Therapeutics Presents Positive New Data Supporting Foundational Role of MIPLYFFA® (arimoclomol) for the Treatment of Niemann-Pick Disease Type C at the International Congress of Inborn Errors of Metabolism (ICIEM)

September 3, 2025

Zevra Therapeutics Announces Multiple Datasets on MIPLYFFA® (arimoclomol) to be Presented at the International Congress of Inborn Errors of Metabolism (ICIEM)

August 27, 2025

Zevra Therapeutics to Participate at Upcoming Investor Conferences in September

August 25, 2025

Zevra Reports Second Quarter 2025 Financial Results and Corporate Update

August 11, 2025

Zevra Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth Conference

August 5, 2025

Zevra Therapeutics Announces Details for Q2 2025 Financial Results Call

August 3, 2025

Zevra Therapeutics Submits Marketing Authorization Application to European Medicines Agency to Review Arimoclomol for the Treatment of Niemann-Pick Disease Type C

July 27, 2025

Zevra Therapeutics Announces MIPLYFFA® and OLPRUVA® Presentations at the Annual Meeting of the Southeastern Regional Genetics Group (SERGG)

July 17, 2025

Zevra Therapeutics Announces Open Label Extension Data Showing Sustained Long-Term Efficacy of MIPLYFFA for the Treatment of NPC Published in the Journal of Molecular Genetics and Metabolism

July 15, 2025

Zevra Therapeutics Announces MIPLYFFA® (arimoclomol) Featured in Presentations at the National Niemann Pick Disease Foundation Conference

July 10, 2025

Zevra Announces Final Results of 2025 Annual Meeting of Stockholders

May 28, 2025

All Three Leading Proxy Advisory Firms – ISS, Glass Lewis, and Egan-Jones – Recommend Zevra Stockholders Vote FOR the Company’s Director Nominees

May 20, 2025

Zevra Reports First Quarter 2025 Financial Results and Corporate Update

May 12, 2025

Zevra Therapeutics Announces Details for Q1 2025 Financial Results Call

May 5, 2025

Zevra Therapeutics to Participate in the Citizens Life Science Conference

April 30, 2025

Zevra Files Definitive Proxy Statement and Mails Letter to Stockholders

April 20, 2025

Zevra Announces Publication of MIPLYFFA® Mechanism of Action Manuscript in Molecular Genetics and Metabolism

April 16, 2025

Zevra Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 Million

April 6, 2025

Zevra Therapeutics Files Preliminary Proxy

March 30, 2025

Zevra Reports Full Year 2024 and Fourth Quarter Financial Results

March 10, 2025

Zevra Launches New Disease State Awareness Campaign, ‘Learn NPC, Read Between the Signs,’ to Drive Early Recognition and Treatment of Niemann-Pick Disease Type C

February 27, 2025

Zevra Therapeutics Enters Agreement to Sell its Rare Pediatric Disease Priority Review Voucher for $150 Million

February 26, 2025

Zevra to Report 2024 Fourth Quarter and Full Year Financial Results

February 25, 2025

Zevra to Participate at Upcoming Investor Conferences

February 23, 2025

Zevra Therapeutics to Present at the 21st Annual WORLDSymposium™

January 29, 2025

Zevra Therapeutics to Participate at Upcoming Investor Conferences

January 28, 2025

Calls in 2025

Decks in 2025